Report Detail

Pharma & Healthcare Smallpox - Pipeline Review, H1 2019

  • RnM2890021
  • |
  • 06 February, 2019
  • |
  • Global
  • |
  • 79 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Smallpox - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Smallpox - Pipeline Review, H1 2019, provides an overview of the Smallpox (Infectious Disease) pipeline landscape.

Smallpox is an acute contagious infection caused by the Variola virus. Symptoms include fever, malaise, headache, prostration, severe back pain, abdominal pain and vomiting. This is followed by the development of rashes on the face, hands, forearms and the trunk. Lesions develop in the mucous membranes of the nose and mouth which ulcerate, releasing large amounts of virus into the mouth and throat. Treatment includes medications such as antiviral and lifestyle modification.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Smallpox - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Smallpox (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Smallpox (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Smallpox and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 1, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Smallpox (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Smallpox (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Smallpox (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Smallpox (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Smallpox (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Smallpox (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Smallpox (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Smallpox (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Smallpox - Overview

              Smallpox - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Smallpox - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Smallpox - Companies Involved in Therapeutics Development

                                      Bavarian Nordic A/S

                                        BioFactura Inc

                                          CEL-SCI Corp

                                            Chimerix Inc

                                              CJ HealthCare Corp

                                                EpiVax Inc

                                                  Fox Chase Chemical Diversity Center Inc

                                                    SIGA Technologies Inc

                                                      Tonix Pharmaceuticals Holding Corp

                                                        Smallpox - Drug Profiles

                                                          24a - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  brincidofovir - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          CEL-1000 - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  CJ-40011 - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          Monoclonal Antibodies for Infectious Disease - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  Monoclonal Antibody for Smallpox - Drug Profile

                                                                                                    Product Description

                                                                                                      Mechanism Of Action

                                                                                                        R&D Progress

                                                                                                          NN-001 - Drug Profile

                                                                                                            Product Description

                                                                                                              Mechanism Of Action

                                                                                                                R&D Progress

                                                                                                                  PL-801 - Drug Profile

                                                                                                                    Product Description

                                                                                                                      Mechanism Of Action

                                                                                                                        R&D Progress

                                                                                                                          smallpox [ankara] vaccine - Drug Profile

                                                                                                                            Product Description

                                                                                                                              Mechanism Of Action

                                                                                                                                R&D Progress

                                                                                                                                  smallpox vaccine - Drug Profile

                                                                                                                                    Product Description

                                                                                                                                      Mechanism Of Action

                                                                                                                                        R&D Progress

                                                                                                                                          tecovirimat - Drug Profile

                                                                                                                                            Product Description

                                                                                                                                              Mechanism Of Action

                                                                                                                                                R&D Progress

                                                                                                                                                  TNX-801 - Drug Profile

                                                                                                                                                    Product Description

                                                                                                                                                      Mechanism Of Action

                                                                                                                                                        R&D Progress

                                                                                                                                                          VIR-002 - Drug Profile

                                                                                                                                                            Product Description

                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                R&D Progress

                                                                                                                                                                  Smallpox - Dormant Projects

                                                                                                                                                                    Smallpox - Discontinued Products

                                                                                                                                                                      Smallpox - Product Development Milestones

                                                                                                                                                                        Featured News & Press Releases

                                                                                                                                                                          Jan 18, 2019: Bavarian Nordic announces exercise of USD 44 million option by the U.S. Government under contract for freeze-dried MVA-BN Smallpox vaccine

                                                                                                                                                                            Dec 21, 2018: Bavarian Nordic announces FDA acceptance and Priority Review of Biologics License Application for MVA-BN Smallpox Vaccine

                                                                                                                                                                              Nov 01, 2018: SIGA announces Priority Review Voucher transaction totaling $80 million

                                                                                                                                                                                Oct 05, 2018: Chimerix presents results from multiple ascending dose study of IV Brincidofovir at IDWeek

                                                                                                                                                                                  Oct 04, 2018: Landmark adVance study shows adenovirus burden correlates with mortality in pediatric allogeneic hematopoietic cell transplant recipients

                                                                                                                                                                                    Sep 19, 2018: Bavarian Nordic delivers Smallpox Vaccine to England in response to current Monkeypox Cases

                                                                                                                                                                                      Sep 10, 2018: SIGA Technologies awarded BARDA contract for TPOXX

                                                                                                                                                                                        Aug 21, 2018: Importance of Smallpox vaccination highlighted in biopreparedness exercise

                                                                                                                                                                                          Aug 09, 2018: Bavarian Nordic Granted EUR 30 Million loan from The European Investment Bank

                                                                                                                                                                                            Jul 13, 2018: FDA approves TPOXX as first drug to treat smallpox

                                                                                                                                                                                              Jul 05, 2018: Pivotal Trial Data for SIGA Technologies’ Oral TPOXX Published in the New England Journal of Medicine

                                                                                                                                                                                                Jun 07, 2018: Chimerix Receives Orphan Drug Designation from the FDA for Brincidofovir for the Treatment of Smallpox

                                                                                                                                                                                                  Jun 05, 2018: Chimerix to Address Congressional Subcommittee in Support of Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA)

                                                                                                                                                                                                    May 31, 2018: SIGA to Present at the Jefferies Global Healthcare Conference on June 8, 2018

                                                                                                                                                                                                      May 01, 2018: SIGA Technologies Announces Favorable Outcome of Advisory Committee In Support of TPOXX

                                                                                                                                                                                                        Appendix

                                                                                                                                                                                                          Methodology

                                                                                                                                                                                                            Coverage

                                                                                                                                                                                                              Secondary Research

                                                                                                                                                                                                                Primary Research

                                                                                                                                                                                                                  Expert Panel Validation

                                                                                                                                                                                                                    Contact Us

                                                                                                                                                                                                                      Disclaimer

                                                                                                                                                                                                                      Summary:
                                                                                                                                                                                                                      Get latest Market Research Reports on Smallpox. Industry analysis & Market Report on Smallpox is a syndicated market report, published as Smallpox - Pipeline Review, H1 2019. It is complete Research Study and Industry Analysis of Smallpox market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                                                                      Last updated on

                                                                                                                                                                                                                      REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                                                      Purchase this Report

                                                                                                                                                                                                                      $2,000.00
                                                                                                                                                                                                                      $4,000.00
                                                                                                                                                                                                                      $6,000.00
                                                                                                                                                                                                                      1,600.00
                                                                                                                                                                                                                      3,200.00
                                                                                                                                                                                                                      4,800.00
                                                                                                                                                                                                                      1,868.00
                                                                                                                                                                                                                      3,736.00
                                                                                                                                                                                                                      5,604.00
                                                                                                                                                                                                                      314,660.00
                                                                                                                                                                                                                      629,320.00
                                                                                                                                                                                                                      943,980.00
                                                                                                                                                                                                                      166,780.00
                                                                                                                                                                                                                      333,560.00
                                                                                                                                                                                                                      500,340.00
                                                                                                                                                                                                                      Credit card Logo

                                                                                                                                                                                                                      Related Reports


                                                                                                                                                                                                                      Reason to Buy

                                                                                                                                                                                                                      Request for Sample of this report